文献速递神经肿瘤

散发性脑膜瘤的多组学整合诊断:其临床意义综述

The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.
PubMed 文献 · J Neurooncol · 2021-11-30

该综述基于PubMed近期同行评议文献与专著,概述脑膜瘤分子特征及其临床意义。特定体细胞驱动突变可区分占散发性脑膜瘤80%以上的主要基因组亚组,并可用无创临床变量区分以辅助管理决策。DNA甲基化是最具临床相关性的表观基因组修饰,多项临床试验正在探索脑膜瘤药物治疗。

要点

  • 特定体细胞驱动突变定义的基因组亚组占散发性脑膜瘤80%以上,可用无创临床变量区分。
  • DNA甲基化是研究最广泛且可能最具临床相关性的表观基因组修饰。
  • 基于分子见解的多项临床试验正在开展,以确立脑膜瘤有效药物治疗方案。

核心结论

  • 随着对脑膜瘤多组学理解的加深,患者诊疗能力将持续改善,进一步的生物学见解将推动脑膜瘤精准医疗进展。

研究设计与样本

  • 基于对近期同行评议文献(PubMed)和专著的全面综述,提供脑膜瘤分子概述并聚焦相关临床意义。

主要发现

  • 特定体细胞驱动突变的识别已将脑膜瘤分类为若干主要基因组亚组,这些亚组占散发性脑膜瘤的80%以上。
  • 这些基因组亚组可通过无创临床变量区分,以帮助指导管理决策。
  • 其他体细胞基因组修饰,包括非编码改变和拷贝数变异,也与肿瘤特征相关。
  • 脑膜瘤的表观基因组修饰近期已被描述,其中DNA甲基化研究最广泛且可能最具临床相关性。
  • 基于这些分子见解,多项临床试验目前正在进行,以确立脑膜瘤的有效药物治疗选择。

关键数值与推荐

  • 特定体细胞驱动突变定义的若干主要基因组亚组占散发性脑膜瘤的80%以上。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Meningiomas are generally considered "benign," however, these tumors can demonstrate variability in behavior and a surprising aggressiveness with elevated rates of recurrence. The advancement of next-generation molecular technologies have led to the understanding of the genomic and epigenomic landscape of meningiomas and more recent correlations with clinical characteristics and behavior. METHODS: Based on a thorough review of recent peer-reviewed publications (PubMed) and edited texts, we provide a molecular overview of meningiomas with a focus on relevant clinical implications. RESULTS: The identification of specific somatic driver mutations has led to the classification of several major genomic subgroups, which account for more than 80% of sporadic meningiomas, and can be distinguished using noninvasive clinical variables to help guide management decisions. Other somatic genomic modifications, including non-coding alterations and copy number variations, have also been correlated with tumor characteristics. Furthermore, epigenomic modifications in meningiomas have recently been described, with DNA methylation being the most widely studied and potentially most clinically relevant. Based on these molecular insights, several clinical trials are currently underway in an effort to establish effective medical therapeutic options for meningioma. CONCLUSION: As we enhance our multiomic understanding of meningiomas, our ability to care for patients with these tumors will continue to improve. Further biological insights will lead to additional progress in precision medicine for meningiomas.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Robert SM, Vetsa S, Nadar A, et al. The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications. J Neurooncol. 2021. PMID: 34846640. doi:10.1007/s11060-021-03874-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。